Triptans have long been the mainstay of acute treatment of migraine, but in Q1 2020, three novel oral nontriptans—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s Nurtec ODT—entered the U.S. market. These therapies offer clinically distinct alternatives to triptans, particularly for patients who cannot tolerate, are contraindicated, or do not adequately respond to triptans. In this report, we leverage national patient-level claims data to assess the relative uptake and performance of these new brands versus the standard of care. Understanding the treatment paradigms and patient flow will provide needed context for developers entering a heavily generic and increasingly saturated market.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Eli Lilly, AbbVie / Allergan, Biohaven Pharmaceuticals, Upsher-Smith, Currax Pharmaceuticals
Key drugs: Reyvow, Ubrelvy, Nurtec ODT, Onzetra Xsail, Tosymra, Zembrace SymTouch, generic triptans, ergot derivatives, Cambia
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, and expanded analyses.